Health Condition 1: H357- Separation of retinal layers
Conditions
Interventions
Intervention1: Subthreshold Micropulse Laser (577nm): Eligible participants will undergo 577-nm Subthreshold Micropulse Laser (SMPL) therapy according to SOLS guidelines. The laser will be applied in
Sponsors
Aravind Eye Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of central serous chorioretinopathy (CSCR) (Presence of subretinal fluid involving the macular area confirmed on OCT/ active leakage documented on fundus fluorescein angiography and/or indocyanine green angiography) causing subretinal fluid (SRF) 2. If Acute CSCR, Patients with No resolution/persistence of SRF following 4 weeks of observation after first visit even after Stress mitigation + Lifestyle modification counselling OR Having clear history of persistent symptoms of duration 4 weeks or more AND Additionally have Visual Acuity of 6/9 BCVA or lesser. 3. Willingness to undergo micropulse laser treatment and follow up
Exclusion criteria
Exclusion criteria: 1. Previous interventional treatment for CSCR (laser, photodynamic therapy, intravitreal injections) 2. Concurrent use of systemic steroids at the time of recruitment into study 3. Coexisting retinal diseases affecting the macula (e.g., age-related macular degeneration, diabetic macular edema, retinal vein occlusion) High myopia, uveitis, glaucoma, or significant media opacity 4. History of ocular trauma or intraocular surgery within the last 6 months 5. Systemic conditions that may confound results (uncontrolled diabetes, uncontrolled hypertension, End Stage Renal Disease) 6. Pregnancy or lactation 7. Inability to comply with follow-up or imaging protocols; contraindicated or previous allergic reactions to FA/ICGA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Demonstration of significant anatomical improvement, including reduction or resolution of subretinal fluid on OCT 2. Improvement or stabilization of best-corrected visual acuity Timepoint: At Baseline, 1 month, 2 months, 4 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To correlate anatomical with functional outcomes, particularly the relationship between SRF height & BCVA. Timepoint: 1 month, 2 months, 4 months & 6 months;To document recurrence rates & need for retreatment, if any, during the follow-up period. Timepoint: 1 month, 2 months, 4 months & 6 months;Subgroup analysis of visual & anatomical outcomes in acute & chronic CSCR cases.Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Siddhi Shanbhag
Aravind Eye Hospitals
Outcome results
None listed